Collagen-binding synthetic peptidoglycans, preparation, and methods of use

Patent metadata

Field	Value
Publication number	US-9512192-B2
Application number	US-201615078885-A
Country	US
Kind code	B2
Filing date	Mar 23, 2016
Priority date	Mar 27, 2008
Publication date	Dec 6, 2016
Grant date	Dec 6, 2016

Abstract

This invention relates to collagen-binding synthetic peptidoglycans and engineered collagen matrices comprising a collagen matrix and a collagen-binding synthetic peptidoglycan where the collagen-binding synthetic peptidoglycan can be aberrant or can have amino acid homology with a portion of the amino acid sequence of a protein or a proteoglycan that regulates collagen fibrillogenesis. The invention also relates to kits, compounds, compositions, and engineered graft constructs comprising such collagen-binding synthetic peptidoglycans or engineered collagen matrices and methods for their preparation and use.

First claim

What is claimed is:

1. A synthetic peptidoglycan comprising a glycan and from 1 to 50 collagen binding peptides, each of which is covalently bonded to the glycan, wherein the peptides comprise amino acids 1-18 (RRANAALKAGELYKSILY) of SEQ ID NO: 1.

2. The peptidoglycan of claim 1 , wherein the peptides comprise SEQ ID NO: 1.

3. The peptidoglycan of claim 1 , wherein the peptides are bonded to the glycan via a linker having a molecular weight of about 20 to about 500 Daltons.

4. The peptidoglycan of claim 1 , wherein the glycan is a glycosaminoglycan.

5. The peptidoglycan of claim 1 , wherein the glycan is alginate, agarose, chondroitin, dermatan, dermatan sulfate, heparan, heparin, keratin, or hyaluronan.

6. The peptidoglycan of claim 1 , wherein the glycan is dermatan sulfate.

7. The peptidoglycan of claim 1 , wherein the glycan is heparin.

8. The peptidoglycan of claim 1 , wherein the peptidoglycan comprises from 1 to 10 of the peptides.

9. A composition comprising the peptidoglycan of claim 1 and a pharmaceutically acceptable excipient or diluent, or a combination thereof.

10. A synthetic peptidoglycan comprising dermatan sulfate and from 1 to 10 collagen binding peptides, all of which are covalently bonded to the dermatan sulfate, wherein the peptides comprise amino acids 1-18 (RRANAALKAGELYKSILY) of SEQ ID NO: 1.

11. A composition comprising the peptidoglycan of claim 10 and a pharmaceutically acceptable excipient or diluent, or a combination thereof.

12. A synthetic peptidoglycan comprising heparin and from 1 to 10 collagen binding peptides, all of which are covalently bonded to the heparin, wherein the peptides comprise amino acids 1-18 (RRANAALKAGELYKSILY) of SEQ ID NO: 1.

13. A composition comprising the peptidoglycan of claim 12 and a pharmaceutically acceptable excipient or diluent, or a combination thereof.

Assignees

• Purdue Research Foundation

Inventors

• Panitch Alyssa
• Paderi John Eric
• Park Kinam
• Stuart Katherine Allison
• Higbee Steve

Classifications

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61L2300/25

  Peptides having up to 20 amino acids in a defined sequence · CPC title

• A61L27/3804

  characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells · CPC title